- Home
- IMAX vs RARE Comparison
IMAX vs RARE Comparison
Compare IMAX & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMAX | RARE |
|---|---|---|
| Founded | 1967 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 1997 | 2013 |
Fundamental Metrics
Financial Performance| Metric | IMAX | RARE |
|---|---|---|
| Price | $42.70 | $23.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 19 |
| Target Price | $43.67 | ★ $66.32 |
| AVG Volume (30 Days) | 944.6K | ★ 2.1M |
| Earning Date | 06-01-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.25 | 7.31 |
| EPS | ★ 0.63 | N/A |
| Revenue | $410,212,000.00 | ★ $673,000,000.00 |
| Revenue This Year | $9.98 | $17.23 |
| Revenue Next Year | $7.45 | $36.13 |
| P/E Ratio | $66.71 | ★ N/A |
| Revenue Growth | 16.47 | ★ 20.13 |
| 52 Week Low | $20.48 | $18.41 |
| 52 Week High | $42.46 | $43.22 |
Technical Indicators
Market Signals| Indicator | IMAX | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 74.81 | 48.43 |
| Support Level | $33.34 | $22.00 |
| Resistance Level | N/A | $25.46 |
| Average True Range (ATR) | 1.65 | 1.29 |
| MACD | 0.56 | 0.25 |
| Stochastic Oscillator | 95.75 | 72.03 |
Price Performance
Historical ComparisonAbout IMAX Imax Corporation
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.